Open AccessEarly experience of seven hepatocellular carcinoma cases treated with regorafenib
Author(s) -
Uchikawa Shinsuke,
Kawaoka Tomokazu,
Aikata Hiroshi,
Kodama Kenichiro,
Inagaki Yuki,
Hatooka Masahiro,
Morio Kei,
Nakahara Takashi,
Murakami Eisuke,
Hiramatsu Akira,
Tsuge Masataka,
Imamura Michio,
Kawakami Yoshiiku,
Chayama Kazuaki
Publication year - 2018
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.1791
Subject(s) - regorafenib , medicine , sorafenib , hepatocellular carcinoma , adverse effect , refractory (planetary science) , oncology , colorectal cancer , cancer , physics , astrobiology
Key Clinical Message Regorafenib became second‐line treatment for the patients with sorafenib refractory. In our study, two patients could not continue regorafenib for its adverse effects. It was suggested that appropriate use criteria of regorafenib should be observed and manage adverse effects earlier.